These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 6861860)

  • 21. [Clearance concept applied to pharmacokinetics: 2. Experience with tolamolol (beta-blocking agent) in renal insufficiency (author's transl)].
    Balant L; Gorgia A; Marmy A; Tschopp JM
    Nephrologie; 1980; 1(4):177-82. PubMed ID: 6895408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The pharmacokinetics of cimetidine and its sulphoxide metabolite in patients with normal and impaired renal function.
    Larsson R; Erlanson P; Bodemar G; Walan A; Bertler A; Fransson L; Norlander B
    Br J Clin Pharmacol; 1982 Feb; 13(2):163-70. PubMed ID: 7059413
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparison of the cardiac effects of triamterene and its phase II metabolite p-hydroxytriamterene sulphuric acid ester (author's transl].
    Greeff K; Schuhmacher P
    Arzneimittelforschung; 1979; 29(4):705-6. PubMed ID: 582773
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Animal experimental and human pharmacologic studies with phase-II metabolites of triamterene].
    Völger KD
    Arzneimittelforschung; 1991 May; 41(5):499-506. PubMed ID: 1898420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acebutolol pharmacokinetics in renal failure.
    Smith RS; Warren DJ; Renwick AG; George CF
    Br J Clin Pharmacol; 1983 Sep; 16(3):253-8. PubMed ID: 6626416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pharmacological effects of phase-I- and phase-II-metabolites of triamterene (author's transl)].
    Knauf H; Mutschler E; Völger KD; Wais U
    Arzneimittelforschung; 1978; 28(8):1417-20. PubMed ID: 582409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The pharmacokinetics of imipenem (thienamycin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure.
    Verpooten GA; Verbist L; Buntinx AP; Entwistle LA; Jones KH; De Broe ME
    Br J Clin Pharmacol; 1984 Aug; 18(2):183-93. PubMed ID: 6593092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
    Lal R; Sukbuntherng J; Luo W; Chen D; Blumenthal R; Ho J; Cundy KC
    Clin Ther; 2012 Jan; 34(1):201-13. PubMed ID: 22206794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man.
    Houin G; Brunner F; Nebout T; Cherfaoui M; Lagrue G; Tillement JP
    Br J Clin Pharmacol; 1983 Sep; 16(3):245-52. PubMed ID: 6626415
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of renal failure, rheumatoid arthritis and old age on the pharmacokinetics of diflunisal.
    Erikson LO; Wåhlin-Boll E; Odar-Cederlöf I; Lindholm L; Melander A
    Eur J Clin Pharmacol; 1989; 36(2):165-74. PubMed ID: 2721541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Elimination of triamterene, an antikaliuretic, and its phenolic metabolite, 2,4,7-triamino-6-p-hydroxyphenylpteridine, in the urine of subjects with normal liver function and in subjects suffering from liver cirrhosis].
    Andrasch H; Fink T; Schmid E
    Z Gastroenterol; 1971; 9(4):240-5. PubMed ID: 5164739
    [No Abstract]   [Full Text] [Related]  

  • 32. Pharmacokinetics and pharmacodynamics of triamterene and hydrochlorothiazide and their combination in healthy volunteers.
    Möhrke W; Knauf H; Mutschler E
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):447-52. PubMed ID: 9352394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antipyrine metabolite formation and excretion in patients with chronic renal failure.
    Teunissen MW; Kampf D; Roots I; Vermeulen NP; Breimer DD
    Eur J Clin Pharmacol; 1985; 28(5):589-95. PubMed ID: 4043202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of chronic renal failure on the pharmacokinetics of ruboxistaurin and its active metabolite 338522.
    Wise S; Yuen E; Chan C; Poo YK; Teng L; Lau T; Voelker J
    Clin Pharmacokinet; 2006; 45(3):297-303. PubMed ID: 16509761
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of renal impairment on disposition of pentopril and its active metabolite.
    Rakhit A; Radensky P; Szerlip HM; Kochak GM; Audet PR; Hurley ME; Feldman GM
    Clin Pharmacol Ther; 1988 Jul; 44(1):39-48. PubMed ID: 3391004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Handling of triamterene by the isolated perfused rat kidney.
    Kau ST
    J Pharmacol Exp Ther; 1978 Sep; 206(3):701-9. PubMed ID: 702330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic fate and solubility of triamterene--not an explanation for triamterene nephrolithiasis.
    Sörgel F; Ettinger B; Benet LZ
    J Pharm Sci; 1986 Feb; 75(2):129-32. PubMed ID: 3958920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [On the bioavailability of hydrochlorothiazide and triamterene from commercial drugs (author's transl)].
    Knauf H; Möhrke W; Mutschler E; Völger KD
    Arzneimittelforschung; 1980; 30(6):1001-4. PubMed ID: 7191258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distribution and pharmacokinetics of triamterene in rats.
    Kau ST; Sastry BV
    J Pharm Sci; 1977 Jan; 66(1):53-6. PubMed ID: 833742
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The influence of age on the pharmacokinetics and pharmacodynamics of bemetizide and triamterene: a single and multiple dose study.
    Mühlberg W; Mutschler E; Hofner A; Spahn-Langguth H; Arnold O
    Arch Gerontol Geriatr; 2001 Jun; 32(3):265-73. PubMed ID: 11395172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.